USP Drug Quality Pilot Program Underway in Sub-Saharan Africa - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Drug Quality Pilot Program Underway in Sub-Saharan Africa


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

On Apr. 18, 2011, scientists from the national laboratories of five African nations gathered in Accra, Ghana, to take part in a week of technical training put on by the US Pharmacopeia (USP) that will teach them how to detect substandard and counterfeit medicines.

USP is providing participants from Ethiopia, Ghana, Kenya, Senegal, and Sierra Leone with pharmaceutical reference standards, documentary standards, and technical writing training in an effort to improve help the quality of those countries’ medicines.  The instruction is a part of a pilot Technical Assistance Program (TAP) that was introduced earlier this year and funded by USP.

USP developed TAP based on feedback from participants about topics they wanted to see addressed most.  National laboratories in these countries often have to rely on unreliable or outdated standards to analyze medicines. The laboratories also may not be equipped to offer analysts the scientific training needed to appropriately analyze medicines.

As a result, accurate outcomes may not be obtained when questionable substances are tested. “Having a team of scientists trained in essential analytical techniques is a fundamental aspect of a well-functioning regulatory system that protects domestic drug supply,” said Patrick Lukulay, director of the PQM program in a USP press release.

The objective of the training is to improve the technical competence of the scientists and familiarize participants with information contained in the USP-NF, including how to use the information, according to the USP release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here